# CD4 cells can be more efficient at tumor rejection than CD8 cells


Ainhoa Pérez-Díez Ghost Lab, Laboratory of Cellular and Molecular Immunology, NIAID, NIH


## Anti-tumor T cells (anti-male)

Name	T cells	H-Y Antigen	Restriction element
MataHari	<b>CD8</b>	Uty	Class I (D <sup>b</sup> )
Marilyn	CD4	Dby	Class II (A <sup>b</sup> )


## The tumor

Name: MB49 Origin: Male B6 bladder carcinoma Antigen: H-Y (Uty and Dby)






#### MataHari but not Marilyn cells are good killers in vitro



#### Marilyn but not MataHari cells reject the tumor



## - Localization?

## - Localization?

## - Tumor escape?

## - Localization?

# - Tumor escape?


# - Tumor-mediated suppression?


## How does Marilyn succeed?

## **Tumor Class II expression** *in vivo*


RagKO

**RagKO+Marilyn** 







A<sup>b</sup> (Class II)




## A<sup>b</sup> shRNA knocks down Class II expression on MB49 cell line



#### Knocking down Class II on MB49 does not affect Marilyn effectiveness




## Or indirectly?



## **Marilyn** can reject indirectly

#### $\beta$ TC-tet tumor



# Is it generalizable?

# Is it generalizable?

- Are Marilyn CD4 better than MataHari CD8 for other tumors?

# Is it generalizable?


- Are Marilyn CD4 better than MataHari CD8 for other tumors?

- Does Marilyn reject other tumors that she cannot see?

#### **Testing other H-2<sup>b</sup> tumors**


TRAMP-C2, a prostate carcinoma

WR21, a salivary gland carcinoma



Days

#### **Testing other H-2<sup>k</sup> tumors**



## CONCLUSIONS

In this male antigen tumor model:

- CD4 cells reject tumors that CD8 cells can't reject
- Neither the effectiveness of CD4 cells nor the ineffectiveness of CD8 cells can be predicted from their *in vitro* activity
- Antigen presentation by the tumor cells is not required for the CD4 mediated rejection

# We need to pay more attention to CD4 cells as effectors.

#### Thank you

## Polly Matzinger

Kyungho Choi

University of Alberta, Edmonton, Canada

William Chan Colin Anderson

Institute Curie, Paris, France

Nathalie Jonker Olivier Lantz